<?xml version="1.0" encoding="UTF-8"?>
<p id="Par42">This studyâ€™s strengths include its prospective cohort design, one of the first such studies conducted in young children with palivizumab-free CF, preventing potential interference of the monoclonal antibody on respiratory viral epidemiology. At home, samples were taken by physiotherapists using a detailed protocol, ensuring collection of good-quality samples.</p>
